The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol.
Pimozide and haloperidol were found to be equally effective in the treatment of acute schizophrenia in a double-blind clinical trial involving 22 patients. Drug plasma levels measured by radioimmunoassay (RIA) did not correlate with clinical response following either drug. Nor was there any correlation between clinical response and the dopamine receptor blocking activity of either drug as measured by radio receptor assay (RRA). Following pimozide plasma prolactin (PRL) levels correlated with clinical change, although the time courses of response of PRL and clinical response were dissimilar. There was no correlation between PRL and clinical response to haloperidol. RRA and RIA values correlated highly following pimozide but not haloperidol. Our findings lead us to conclude that the RRA technique reflects the plasma level of a drug rather than its central dopamine blocking activity. We also consider that the clinical response to antipsychotic drugs in schizophrenia may be less directly linked to dopamine receptor blockade than has previously been supposed.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010868:Pimozide / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D011863:Radioimmunoassay; D011869:Radioligand Assay; D011954:Receptors, Dopamine / Q000032:analysis / Q000187:drug effects*; D012559:Schizophrenia / Q000188:drug therapy*
D011954:Receptors, Dopamine; D010868:Pimozide; D011388:Prolactin; D006220:Haloperidol